6622 Stock Overview
An ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zhaoke Ophthalmology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.36 |
| 52 Week High | HK$4.44 |
| 52 Week Low | HK$1.28 |
| Beta | 0.97 |
| 11 Month Change | 2.26% |
| 3 Month Change | -1.45% |
| 1 Year Change | -67.92% |
| 33 Year Change | -78.98% |
| 5 Year Change | n/a |
| Change since IPO | -90.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6622 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -1.4% | 1.1% | 1.6% |
| 1Y | -67.9% | -9.4% | 10.1% |
Return vs Industry: 6622 underperformed the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 6622 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 6622 volatility | |
|---|---|
| 6622 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 6622 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6622's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 297 | Benjamin Li | www.zkoph.com |
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited.
Zhaoke Ophthalmology Limited Fundamentals Summary
| 6622 fundamental statistics | |
|---|---|
| Market cap | HK$742.75m |
| Earnings (TTM) | -HK$244.05m |
| Revenue (TTM) | HK$61.50m |
12.1x
P/S Ratio-3.0x
P/E RatioIs 6622 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6622 income statement (TTM) | |
|---|---|
| Revenue | CN¥57.22m |
| Cost of Revenue | CN¥10.28m |
| Gross Profit | CN¥46.93m |
| Other Expenses | CN¥274.00m |
| Earnings | -CN¥227.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 82.03% |
| Net Profit Margin | -396.86% |
| Debt/Equity Ratio | 11.0% |
How did 6622 perform over the long term?
See historical performance and comparison